Guidepoint Qsight, a leader in leveraging proprietary data to provide unmatched analytics solutions, today revealed new ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Jonathan Van Ness is seen on the Netflix show, Queer Eye. He has, for the first time, spoken publicly about using weight loss ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

“Alright, I have a confession to make. Yes, I am on a GLP-1 for a weight-loss medication,” Van Ness said.

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.

Weight gain after a breast cancer diagnosis elevated a person’s risk for heart failure, according to results of an observational study in the Republic of Korea.Researchers did not observe any ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...